PYC Therapeutics (PYC) Q1 2026 earnings summary

Executive summary

• Recent financing has strengthened the balance sheet, providing over $750 million in cash and enabling advancement of four pipeline assets through human efficacy readouts and potentially into late-stage development independently.

• Tier 1 specialist investors have joined, aligning incentives and providing strategic industry connections, with a strong shareholder base of leading global life science investors.

• The company focuses on RNA therapeutics and disease-modifying therapies for severe genetic diseases with high unmet need, leveraging genetically validated targets and patient-derived models to de-risk development.

• Pipeline includes four clinical-stage assets aiming for human efficacy data in 2026/2027, addressing severe unmet medical needs.

Financial highlights

• Upon closure of the retail entitlement offer, total funds raised will be AUD 600–650 million, providing a cash runway exceeding $750 million gross and ensuring operational funding through 2030.

• Strong shareholder register with substantial new investment, including AUD 333.3 million worth of stock allocated to new investors at the same price as the entitlement offer.

Outlook and guidance

• All four pipeline assets are expected to deliver human safety and efficacy data within the next 24 months, with multiple near-term readouts and advancement into registrational trials mapped through 2030.

• The Polycystic Kidney Disease (PKD/ADPKD) program is advancing to repeat dose studies in Q2, with key biomarker and anatomical endpoints ahead.

• Phelan-McDermid syndrome program delayed by 12 months due to requirements for juvenile toxicology studies, targeting IND submission in Q1 next year.

• Ophthalmology programs (RP11 and ADOA) are awaiting long-term efficacy data and regulatory alignment before phase III initiation.